Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Rituximab 41Cyclophosphamide 37Magnetic Resonance Spectroscopy 22Specimen Handling 20Prednisone 19Doxorubicin 19polatuzumab vedotin 18Lenalidomide 17Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13Vincristine 12zanubrutinib 11Immunotherapy, Adoptive 11Etoposide 10glofitamab 8obinutuzumab 7axicabtagene ciloleucel 7Prednisolone 7ibrutinib 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6CT-P10 6Bendamustine Hydrochloride 6orelabrutinib 5loncastuximab tesirine 5fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × Maintenance × Clear all
NCT06503263 2024-09-19

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Navy General Hospital, Beijing

Phase 2 Recruiting
240 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡